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Abstract Diclofenac is a nonsteroidal anti-inflammatory
drug (NSAID) of the phenylacetic acid class with anti-
inflammatory, analgesic, and antipyretic properties. Con-
trary to the action of many traditional NSAIDs, diclofenac
inhibits cyclooxygenase (COX)-2 enzyme with greater
potency than it does COX-1. Similar to other NSAIDs,
diclofenac is associated with serious dose-dependent gas-
trointestinal, cardiovascular, and renal adverse effects.
Since its introduction in 1973, a number of different di-
clofenac-containing drug products have been developed
with the goal of improving efficacy, tolerability, and pa-
tient convenience. Delayed- and extended-release forms of
diclofenac sodium were initially developed with the goal of
improving the safety profile of diclofenac and providing
convenient, once-daily dosing for the treatment of patients
with chronic pain. New drug products consisting of di-
clofenac potassium salt were associated with faster ab-
sorption and rapid onset of pain relief. These include
diclofenac potassium immediate-release tablets, diclofenac
potassium liquid-filled soft gel capsules, and diclofenac
potassium powder for oral solution. The advent of topical
formulations of diclofenac enabled local treatment of pain
and inflammation while minimizing systemic absorption of
diclofenac. SoluMatrix diclofenac, consisting of submicron
particles of diclofenac free acid and a proprietary combi-
nation of excipients, was developed to provide analgesic
efficacy at reduced doses associated with lower systemic
absorption. This review illustrates how pharmaceutical
technology has been used to modify the pharmacokinetic
properties of diclofenac, leading to the creation of novel
drug products with improved clinical utility.
Key Points
Since its introduction, the original diclofenac sodium
drug product has been modified using
pharmaceutical technology.
Alteration of the pharmacokinetic properties of oral
diclofenac drug products produced a number of
desirable characteristics, including more convenient
dosing, improved absorption, and rapid onset of
analgesia.
Development of topical diclofenac drug products
improved tolerability and reduced systemic exposure
to the drug, and improvements have been seen
recently in diclofenac drug products for injection.
Recently, a new technology that reduces drug
particle size has been used to develop low-dose oral
diclofenac products that provide analgesic efficacy
with low systemic exposures.
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In recent decades, novel methods for chemical syn-
thesis and improved analytical and screening tech-
nologies have spurred the creation of new nonsteroidal
anti-inflammatory drug (NSAID) products [1–5]. In
parallel, advances in pharmaceutics, along with the
science of developing physical medicinal dosing forms
such as tablets and capsules, have also been used to
improve the pharmacological properties of these agents.
These advances include development of controlled drug
delivery systems and novel oral drug preparations such
as flexible, dispersible, or multiparticulate dosage
forms [6]. Furthermore, new manufacturing technolo-
gies that modify the particle size distribution of the
active drug substance have enhanced the dissolution,
bioavailability, and efficacy of oral drug products [7].
These improvements have provided clinical benefits
such as reduced dosing frequency and improved ad-
verse event profile.
Advances in NSAID pharmaceutics have recently
been focused on the development of options to address
serious dose-dependent gastrointestinal (GI), cardio-
vascular (CV), and renal adverse effects (AEs) asso-
ciated with the use of NSAIDs [8–15]. Approaches to
address these concerns have concentrated on modifi-
cations of pharmacological properties, novel modes of
delivery, and co-administration with gastroprotective
agents such as proton pump inhibitors, with the main
goal of improving tolerability and, in some cases,
supporting expanded indications.
Diclofenac is the most widely prescribed NSAID
worldwide [14]. More than 10 million diclofenac drug
product prescriptions were dispensed in the USA in
2012 [16]. Since its introduction in 1973 [17, 18], a
number of new diclofenac-containing drug products
have been approved for use and marketed in the USA
(Table 1). The growth in NSAID prescriptions in the
USA has been driven in part by the introduction of
new diclofenac drug products [19]. These new products
have varied pharmacokinetic (PK) properties and dos-
ing regimens and are indicated for the treatment of a
range of acute and/or chronic pain conditions [20, 21].
The development of diclofenac drug products demon-
strates how pharmaceutical technology can be used to
drive innovation, creating drug products with improved
efficacy, safety, and increased clinical utility.
We review the history leading to the invention of
NSAIDs, including diclofenac, and summarize advances in
the development of diclofenac drug products, with primary
emphasis on the modifications of the PK properties of di-
clofenac implemented to improve its efficacy and safety.
1.1 Search Strategy
We performed a literature search in National Library of
Medicine/PubMed to identify potential articles during the
period 1 January 1970 to 30 September 2014 using the
following search terms alone or in combinations: NSAID,
diclofenac, development, diclofenac sodium, diclofenac
potassium, extended-release, enteric-coated, sustained-re-
lease, controlled-release, delayed-release, immediate-re-
lease, diclofenac topical, diclofenac epolamine, diclofenac
free acid, ProSorb, SoluMatrix, submicron, milling tech-
nologies, dispersion technologies, diclofenac gel, diclofe-
nac solution, diclofenac powder, diclofenac
pharmacokinetics, diclofenac delivery, diclofenac dissolu-
tion, diclofenac potassium liquid-filled soft gelatin cap-
sules, DPSGC, diclofenac AND gastroprotective agents,
diclofenac AND proton pump inhibitors, diclofenac AND
fixed dose combination, diclofenac AND misoprostol, and
diclofenac AND omeprazole. Search terms with high sen-
sitivity and low specificity were chosen to produce a
comprehensive list of search results. Published articles and
abstracts were reviewed to identify additional references
that were considered relevant. Clinical studies cited in the
review were those designed to characterize the biophar-
maceutical properties or definitively characterize clinical
efficacy in well-controlled phase III pivotal studies and are
included for illustrative purposes. A comparison of clinical
studies that were identified using this strategy with studies
obtained using a broader search strategy did not identify
additional relevant studies.
2 Development of Nonsteroidal
Anti-Inflammatory Drugs and Diclofenac
The active compound of willow bark, salicin, an historical
medicinal remedy, is metabolized to salicylic acid, which
has antipyretic, analgesic, and anti-inflammatory properties
[22–24]. In the late nineteenth century, salicylic acid was
used throughout the world for a variety of ailments [22].
Because of its bitter taste and concomitant gastric irritation,
there was a need for new, improved chemical derivatives of
salicylic acid. In 1897, Felix Hoffman and Arthur
Eichengru¨n acetylated the salicylic acid molecule to pro-
duce a weakly acidic acetylsalicylic acid with a more
palatable taste, which was patented by Bayer (Berlin,
Germany) as aspirin in 1899 [23, 25].
In the early 1950s, the Geigy Company (Basel,
Switzerland) discovered a new compound that formed
water-soluble salts of aminophenazone, with potent anti-
inflammatory and uric acid excretion-promoting activity
[26, 27]. This compound, a pyrazolidine derivative named
phenylbutazone, became the first non-salicylate NSAID




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Evolution of Diclofenac Drug Products 861
administered to patients with ankylosing spondylitis, gout,
rheumatoid and psoriatic arthritis, and mixed connective
tissue disease [27, 41]. The development of biological
screening assays and preclinical models of inflammation
represented a major advance in drug discovery and enabled
screening of large numbers of chemical compounds for anti-
inflammatory activity. This development led to the discovery
of indomethacin, the first acetic acid derivative with anti-
inflammatory properties, in the late 1950s, by Shen et al. [42].
It was not until 1971 that the molecular mechanism respon-
sible for NSAID activity was discovered when John Vane
demonstrated that acetylsalicylic acid and NSAIDs inhibited
the activity of cyclooxygenase enzymes responsible for the
conversion of arachidonic acid to prostanoids [43].
The discovery of the NSAID mechanism of action re-
sulted in the development of a wide array of new NSAIDs,
including propionic acid derivatives (e.g., ibuprofen) and
fenamic acid derivatives (e.g., mefenamic acid) [44].
During this period, analysis of structural and physico-
chemical properties of the existing NSAIDs provided a
theoretical basis for synthesis of new anti-inflammatory
agents with enhanced efficacy [45]. Based on the results of
this analysis, this hypothetical agent was postulated to have
an acidity constant between 4 and 5; a partition coefficient
of approximately 10; and two aromatic rings that were
twisted in relation to each other [45, 46]. These specific
physicochemical and spatial characteristics were an-
ticipated to ensure efficient transport across biological
membranes and to promote strong inhibition of the cy-
clooxygenase (COX)-dependent oxidation of the arachi-
donic acid molecule [45, 46].
Based on this information, diclofenac sodium was syn-
thesized by Alfred Sallmann and Rudolf Pfister and first
introduced by Ciba-Geigy (now Novartis AG, Basel,
Switzerland) in 1973 [17, 18]. Diclofenac is a phenylacetic
acid with an acidity constant of 4, establishing it as a weak
acid, and a partition coefficient of 13.4, indicating partial
solubility in both aqueous and hydrophobic environments.
The structural features of the molecule, namely a
phenylacetic acid group and a phenyl ring containing two
chlorine atoms, produce maximal twisting of the phenyl
ring (Fig. 1) and provide a good fit in the substrate-binding
pocket of the COX enzyme [46, 47]. Subsequent ex-
perimental and clinical studies confirmed the theoretical
considerations that led to the synthesis of diclofenac.
3 General Properties of Diclofenac
3.1 Mechanism of Action
Diclofenac belongs to a group of NSAIDs that inhibit both
COX-1 and COX-2 enzymes. The binding of NSAIDs to
COX isozymes inhibits the synthesis of prostanoids (i.e.,
prostaglandin [PG]-E2, PGD2, PGF2, prostacyclin [PGI2],
and thromboxane [TX] A2) [43, 48, 49]. PGE2 is the
dominant prostanoid produced in inflammation, and the
inhibition of its synthesis by NSAIDs is believed to be the
main mechanism of the potent analgesic and anti-inflam-
matory properties of these agents [49–51].
The human whole blood in vitro assay developed by
Paola Patrignani and colleagues [52] has been used to
measure the degree of selectivity of NSAIDs toward COX-
2 or COX-1 by quantifying the inhibition of COX-2—de-
pendent formation of PGE2 produced by monocytes, fol-
lowing lipopolysaccharide (LPS) stimulation versus COX-
1–dependent formation of TXB2, the non-enzymatic hy-
drolysis product of TXA2 produced by platelets [53].
Although diclofenac is commonly referred to as a tradi-
tional NSAID in the published literature, these assays have
demonstrated that it has a higher selectivity for COX-2
than for COX-1, in contrast with most traditional NSAIDs.
The degree of COX-2 selectivity demonstrated for di-
clofenac is comparable to that of celecoxib [51]. Diclofe-
nac is more potent in inhibiting COX-2 than COX-1
isoenzymes. However, the estimated IC50 (concentration
causing 50 % inhibition of activity) values for COX-1 and
COX-2 of different COX inhibitors has been shown to vary
Fig. 1 Chemical structure of
diclofenac drug products
862 R. Altman et al.
between models, and selectivity is dose dependent in some
cases [49, 54–56].
3.2 Adverse Events and Drug–Drug Interactions
Diclofenac, similar to other NSAIDs, is associated with
an increased risk of serious dose-related GI, CV, and
renal side effects [8, 10–13, 15]. The GI AEs occur due
to reduced synthesis of prostanoids, limiting secretion of
mucus and bicarbonate that normally protect the gastric
mucosa from injury [44, 57]. Consistent with the hy-
pothesis that NSAIDs associated with the highest COX-1
selectivity are more likely to be associated with an in-
creased risk of GI toxicity [56, 58], diclofenac ranks low
in terms of relative risk for GI complications, especially
when administered at low doses (B75 mg daily) [56, 59–
61]. The GI toxicity of this agent is dependent on high
diclofenac levels in the systemic circulation [58]. PGI2, a
major product of COX-2—mediated metabolism of
arachidonic acid in vascular endothelial cells, serves a
physiologic function as a potent vasodilator and platelet
inhibitor [62]. Both preclinical and clinical evidence
indicate that suppression of PGI2 synthesis increases the
risk for hypertension and thrombosis [9, 63, 64]. The
dose-related risk of thrombotic events, especially fol-
lowing administration of high doses of diclofenac
(C150 mg daily), has been documented in observational
studies [9, 58]. The CV hazard of diclofenac at dos-
es C150 mg daily is estimated to be comparable to that
of rofecoxib and celecoxib, as well as ibuprofen ad-
ministered at high doses [9, 15]. The variable risk of
myocardial infarction (MI) due to NSAIDs that do not
completely inhibit COX-1 is largely related to their ex-
tent of COX-2 inhibition [55]. Because the incidence of
AEs is dose dependent, a reduction of the diclofenac
dose is advisable for patients with risk factors for the
development of CV and GI adverse events [55].
Low-dose aspirin (75–150 mg daily) prevents the ag-
gregation of platelets and is commonly used in the phar-
macological prevention of CV disease [65]. An important
clinical issue is the potential interference of NSAIDs with
the antiplatelet effects of low-dose aspirin when co-ad-
ministered with NSAIDs in patients with CV disease. The
irreversible inhibition of platelet COX-1 activity by aspirin
requires initial low-affinity anchoring to the Arginine-120
residue of the COX channel, which is a common docking
site shared by other NSAIDs. Thus, NSAIDs that inhibit
platelet COX-1, such as ibuprofen [66, 67] or naproxen
[68, 69], could interfere with the antiplatelet effects of low-
dose aspirin. In contrast, diclofenac and the selective COX-
2 inhibitors rofecoxib and celecoxib do not interfere with
aspirin action on platelets [66, 67]. Measurement of the
extent of COX-1 acetylation in platelets by mass
spectroscopy may shed additional light on the mechanistic
aspects of this clinically relevant drug–drug interaction
[70].
3.3 General Pharmacokinetic Properties
of Diclofenac
Following oral administration, systemic absorption of di-
clofenac is generally rapid and directly proportional to the
dose [71, 72]. The rate of diclofenac absorption may vary
depending on the salt form, pharmaceutical composition,
and timing of administration in relation to food intake. The
absorption of diclofenac can be inconsistent, with variable
maximum plasma concentration (Cmax) and time to Cmax
(tmax), as well as the presence of late or secondary plasma
peaks in plots of diclofenac concentration versus time [73–
77]. It has been proposed that these inconsistences in di-
clofenac absorption arise due to individual subject differ-
ences in GI pH [78], partial precipitation of the dose in the
acidic conditions in the stomach [79, 80], variable timing in
gastric emptying, and enterohepatic circulation [81, 82].
Approximately 60 % of the intact diclofenac reaches the
systemic circulation due to first-pass metabolism [20, 71].
The main metabolite, 40-hydroxydiclofenac, is known to
retain weak anti-inflammatory and analgesic activities [83].
Following biotransformation to glucoroconjugated and
sulphate metabolites, diclofenac is excreted in the urine
[20, 71]. Diclofenac is eliminated through metabolism and
subsequent urinary and biliary excretion. Both diclofenac
and its oxidative metabolites undergo glucuronidation or
sulfation followed by biliary excretion. Approximately
65 % of the dose is excreted in the urine and 35 % in the
bile as conjugates of unchanged diclofenac and its
metabolites [28].
Acidic NSAIDs are highly bound to plasma proteins,
mainly albumin. Diclofenac, similar to other acidic
NSAIDs, concentrates not only in the systemic circula-
tion, but also in inflamed tissues where the weak acidic
environment reduces plasma protein binding, thereby in-
creasing the free fraction of the drug and facilitating
diffusion of diclofenac into the intracellular spaces where
it can exert its therapeutic effect [26, 84, 85]. Diclofenac
accumulates in synovial fluid at levels that eventually
exceed plasma levels and that persist after the plasma
levels have substantially decreased. Diclofenac adminis-
tered as the sodium salt was detectable in synovial fluid
for up to 11 h following administration of a 50-mg en-
teric-coated tablet [83] and up to 25 h following ad-
ministration of a 100-mg slow-release tablet [83, 86, 87].
Whether diffusion into the synovial fluid of joints ac-
counts for the therapeutic efficacy of diclofenac is un-
known; its persistence at the site of inflammation, and its
inhibition of COX-2 enzymes in the inflammatory cells,
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could explain the duration of diclofenac therapeutic effect
that extend beyond the plasma half-life. However, the
prolonged therapeutic effect of diclofenac could also be
related to its extended pharmacodynamic half-life after
administration of high doses [56, 88]. Several studies
have shown that treatment with diclofenac sodium sig-
nificantly decreases the synovial fluid levels of PGE2 [87]
as well as those of inflammatory cytokines such as in-
terleukin-6 and substance P [89].
Because of its short biological half-life (*2 h) [71, 72,
90] and fast elimination rate (mean elimination half-life
1.2–1.8 h) [20, 71, 90, 91], frequent administration of di-
clofenac is usually necessary to maintain its therapeutic
concentration, which could in turn increase the risk for
adverse events. However, the relatively short pharmaco-
logical half-life of diclofenac may be extended, since, at
therapeutic doses, the Cmax [88] is greater than that nec-
essary to inhibit COX-2 by 80 % [56], indicating that ef-
ficacy could be achieved at lower diclofenac doses.
The requirement for frequent dosing due to the rapid
elimination rate was anticipated to potentially compromise
the tolerability of diclofenac. To minimize damage to the
stomach and to make the dosing regimen of diclofenac
safer and more convenient for patients, modified-release
dosage forms have been introduced. Oral diclofenac sodi-
um formulations available include enteric-coated tablets
[90, 91], which have found their main therapeutic niche in
the treatment of rheumatoid arthritis. Intravenous diclofe-
nac formulations have been developed to treat moderate
pain or more severe pain as an adjunct to more potent
agents, such as opioids, for perioperative pain [40, 92].
Topical formulations, as liquid solutions, gels, or trans-
dermal patches permitting dermal delivery, have been de-
veloped for the treatment of certain types of localized pain
[93].
4 Oral Preparations of Diclofenac Sodium
4.1 Diclofenac Sodium Enteric-Coated Tablets
for the Treatment of Chronic Pain
Introduced in the late 1980s, diclofenac sodium enteric-
coated (delayed-release) tablets (Voltaren, Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA)
was the first diclofenac drug product aimed at reducing
gastric exposure. A polymeric coating was developed to
modify the final site of drug delivery in the digestive
system. The pH-sensitive barrier applied to these tablets
resisted dissolution in the acidic environment of the
stomach, but allowed release of diclofenac on reaching
the higher pH environment of the small intestine [21,
94]. Enteric coating involves a fine balance: the higher
pH required for dissolution of the coating could lead to
inconsistent release of the active diclofenac ingredient.
Furthermore, although bypassing the gastric mucosa
could potentially reduce the risk of gastroduodenal ulcers,
the possibility of transferring the direct mucosal effects
of the drug to distal parts of the gastrointestinal tract is
still of potential clinical concern [78].
Diclofenac absorption following administration of en-
teric-coated diclofenac sodium tablets is usually delayed by
approximately 0.5–2 h, although some tablets may remain
in the stomach void for up to 24 h [79]. Once the active
ingredient is released in the stomach, Cmax is usually at-
tained within 0.5–1.5 h after ingestion of a 50-mg tablet
[78, 79] (Table 2).
A number of clinical studies have confirmed the anti-
inflammatory and analgesic efficacy of diclofenac sodium
enteric-coated tablets in patients with rheumatoid arthritis,
osteoarthritis, ankylosing spondylitis, and acute gout. Di-
clofenac sodium enteric-coated tablets were, at one time,
considered the benchmark for pharmacological treatment
for osteoarthritis [95–97]. In randomized controlled studies
in patients with osteoarthritis of the hip and/or knee,
treatment with enteric-coated tablets provided better pain
relief and substantial functional improvement compared
with placebo [98]. Diclofenac sodium was non-inferior to
indomethacin [99], ibuprofen [100], naproxen [101, 102],
and other NSAIDs [98].
Adverse events reported for diclofenac enteric-coated
tablets were generally similar to those reported for other
NSAIDs. The most frequent GI AEs included abdominal
pain, constipation, diarrhea, indigestion, and nausea [20].
Diclofenac sodium enteric-coated tablets caused fewer di-
gestive (nausea, vomiting, abdominal discomfort) and
central nervous system-associated (headache, dizziness)
side effects than aspirin or indomethacin [20, 103, 104] and
were associated with fewer endoscopically confirmed
hemorrhagic and erosive lesions in the GI mucosa than
naproxen [104, 105].
4.2 Diclofenac Sodium Extended-Release Tablets
for Treatment of Chronic Pain
Diclofenac sodium extended-release tablets (Voltaren-
XR, Novartis Pharmaceuticals Corporation) were intro-
duced in the late 1990s [106, 107]. This drug product
was designed to continuously release active diclofenac
over an extended period of time, permitting once-daily
dosing with the 100-mg tablet in patients with chronic
pain associated with osteoarthritis and rheumatoid
arthritis [30, 108]. Extended-release diclofenac sodium
tablets consisted of a multilayer matrix, with the outer
layer of hydroxypropylmethylcellulose alternating with
drug substance [88]. The outer layer of these tablets
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expands during dissolution but is not subjected to erosion
and acts as a barrier that regulates drug release. The
inner, erodible layer enables progressive dissolution of
the active drug substance, thus extending the time of
release and drug delivery [106]. Extended-release di-
clofenac delivers the total drug content slowly over the
course of 8–10 h [83]. The dissolution behavior of this
drug product may vary depending on physiological con-
ditions or physical stress [117]. Despite similar
bioavailability compared with enteric-coated tablets, the
extended-release diclofenac sodium tablets are associated
with a lower Cmax and delayed tmax [66, 85–87]
(Table 2).
In patients with rheumatoid arthritis or osteoarthritis,
the efficacy of diclofenac sodium sustained-release for-
mulation was comparable to that of nabumetone [118]
and meloxicam [119]. Furthermore, in patients with
chronic pain due to osteoarthritis of the hips and/or
knees, diclofenac sodium extended-release tablets were
shown to be as effective as controlled-release tramadol,
an opioid analgesic [120]. Significantly more patients
with osteoarthritis receiving diclofenac 75-mg sustained-
release tablets twice daily experienced ‘‘good’’ (defined
as C90 %) compliance compared with patients receiving
enteric-coated 50-mg tablets three times daily [121].
Although the relative risk of serious GI complications
with diclofenac was estimated as low compared with
other NSAIDs [122], the hazard of developing gas-
tric/duodenal ulcers and upper GI perforation and
bleeding was not eliminated with the use of enteric-
coated or extended-release tablets [123]. More recent
data from observational studies suggest that administra-
tion of diclofenac drug products with extended half-lives
(i.e., slow- or extended-release forms) are associated
with an elevated risk of serious GI and CV events [30,
55]. It is postulated that persistent inhibition of COX-1
and COX-2 in the systemic circulation may limit the
opportunity for recovery by endogenous COX enzymes
[84].
5 Diclofenac Sodium and Gastroprotective
Therapies
Endoscopic evaluation of patients with rheumatoid arthritis
or osteoarthritis who used NSAIDs continuously over a
period of 6 months revealed clinically significant gastro-
duodenal lesions in 37 % and ulceration in 24 % of cases
[124]. To reduce the risk for serious GI AEs associated
with long-term use of diclofenac sodium, combination
therapies based on co-administration of diclofenac along
with gastroprotective agents such as prostaglandin analogs
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5.1 Diclofenac Sodium and Misoprostol Fixed-Dose
Combination
A fixed-dose combination diclofenac sodium-misoprostol
(ARTHROTEC, G.D. Searle LLC Division of Pfizer Inc.,
New York, NY, USA) [31] sequential-release tablet was
approved by the US FDA in 1997 for the treatment of signs
and symptoms of osteoarthritis and rheumatoid arthritis in
patients at high risk for developing NSAID-induced gas-
tric/duodenal ulcers and related complications. The tablet
is composed of an enteric-coated diclofenac sodium core
(50 or 75 mg) and an outer shell containing misoprostol
(200 lg), a synthetic prostaglandin analog, with gastric
antisecretory and mucosal protective properties [108].
Studies reported that diclofenac and misoprostol do not
interact with each other, exhibit similar absorption rates,
display elimination half-lives of \2 h, and do not accu-
mulate in plasma after recommended doses [125]. Phar-
macokinetic properties of diclofenac sodium in the fixed-
dose combination with misoprostol were generally similar
to those of enteric-coated diclofenac sodium when ad-
ministered as monotherapy [125]. On average, mean Cmax
was approximately 1.5 or 2.0 lg/mL for 50 or 75-mg
doses, respectively, and was usually attained within 2 h
after dosing [31].
A fixed-dose combination of diclofenac sodium/miso-
prostol was shown to be as efficacious as indomethacin,
diclofenac, ibuprofen, naproxen, or piroxicam in the relief
of signs and symptoms of rheumatoid arthritis or os-
teoarthritis [126, 127]. In endoscopic studies, a lower in-
cidence of both gastric and duodenal ulcers was noted in
the groups receiving diclofenac/misoprostol therapy com-
pared with sodium diclofenac treatment alone. GI and
duodenal ulcers were significantly less frequent in patients
with osteoarthritis of the hip or knee and previous history
of gastric ulcers after 6 weeks of therapy with a fixed-dose
combination of diclofenac 50 mg/misoprostol 200 lg three
times daily (8 %), diclofenac 75 mg/misoprostol 200 lg
twice daily (7 %), or placebo (4 %) compared with patients
receiving enteric-coated diclofenac sodium 75 mg twice
daily (17 %) [128]. In a study in a similar patient popula-
tion at risk for NSAID-induced ulcers, fewer patients ad-
ministered enteric-coated diclofenac/misoprostol
combination for 12 weeks developed gastroduodenal ulcers
(4 %) compared with diclofenac-treated patients (11 %;
P = 0.034) [127]. The combined incidence of endo-
scopically confirmed gastric and duodenal ulcers was also
significantly lower in the diclofenac/misoprostol therapy
group (4 %) than in the nabumetone-treated group (11 %)
[129].
Adverse events following administration of diclofenac/
misoprostol generally did not differ between the active
treatment groups, except for higher rates of flatulence and
diarrhea in patients receiving misoprostol [128]. These
findings were consistent with earlier clinical studies that
reported that misoprostol was associated with dose-de-
pendent GI AEs, the most common of which included di-
arrhea and abdominal cramps, at the dose of 200 lg four
times daily [130, 131]. Lower doses of misoprostol were
better tolerated, but were less effective at preventing en-
doscopically confirmed gastric ulcers [132]. Despite the
impact on reducing the risk of endoscopically proven ul-
cers, the presence of these unpleasant GI effects has limited
the general acceptance of the diclofenac/misoprostol
combination.
5.2 Diclofenac Sodium and Omeprazole
Combination
Although no fixed-dose combinations of diclofenac and
proton pump inhibitors have been developed to date, sev-
eral clinical studies have evaluated the efficacy and safety
of co-administration enteric-coated or extended-release
sodium diclofenac with omeprazole in patients with os-
teoarthritis or rheumatoid arthritis who had developed
gastroduodenal ulcers after long-term treatment with di-
clofenac or other NSAIDs.
No drug–drug interactions were demonstrated for
omeprazole and diclofenac. Omeprazole administered
20 mg daily had no significant influence on the pharma-
cokinetic properties of enteric-coated diclofenac sodium
50-mg tablets [133].
Co-administration of omeprazole reduced the risk of
ulcer formation [134] and bleeding from recurrent ulcers
[135] and accelerated healing of the existing ulcers in pa-
tients with a previous history of gastric or duodenal ulcers
associated with long-term NSAID administration [136].
Omeprazole-related side effects were mostly mild and
transient and included diarrhea and dry mouth [136]. Be-
cause of their efficacy and good tolerability, proton pump
inhibitors are the main acid-reducing medication used to
prevent ulcers related to NSAIDs [137]. However, the
proton pump inhibitors do not protect against injury to the
lower GI tract [71, 78, 138].
6 Oral Preparations of Diclofenac Potassium
The unpredictable absorption profile of diclofenac sodium
was initially suggested to explain delays in the analgesic
onset and efficacy of the drug [115]. Diclofenac potassium
salt is more water soluble and was considered to provide
more rapid dissolution and faster absorption than sodium
salt, leading to more uniform absorption and shortened
time to onset of analgesia [81]. These characteristics of
diclofenac potassium products were confirmed by several
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pharmacokinetic and clinical studies (Table 2) [21, 76,
112, 113, 115].
As a reflection of the rapid absorption kinetics, di-
clofenac potassium is usually indicated for conditions that
require a rapid onset of analgesia. A number of diclofenac
potassium drug products are available in the USA, in-
cluding immediate-release tablets [139], liquid-filled soft
gelatin diclofenac capsules [140], and diclofenac powder
for oral solution [141].
6.1 Diclofenac Potassium Immediate-Release
Tablets
Diclofenac potassium immediate-release sugar-coated
tablets (Cataflam, Novartis Pharmaceuticals Corporation)
were developed in the early 1980s [139] with the aim of
releasing the active drug in the stomach to permit rapid
uptake and prompt pain relief [139]. Pharmacokinetic
studies in healthy volunteers showed that the differences in
the absorption characteristics between immediate-release
potassium and enteric-coated sodium diclofenac tablets
were notable. The Cmax achieved after administration of a
diclofenac potassium immediate-release 50-mg tablet was
slightly lower (Table 2), but the tmax was substantially
shorter (range 0.63–1.26 h) than that of a diclofenac
sodium enteric-coated 50-mg tablet (range 1.13–2.75 h;
Table 2) [76, 112, 113, 115]. In some studies, secondary
diclofenac absorption peaks were not observed [76, 115].
Clinical studies evaluated the efficacy and safety of di-
clofenac potassium immediate-release tablets in various
conditions characterized by the acute onset of pain, such as
pain following removal of impacted molars [140], ankle
sprains [141–143], episiotomy [144], and dysmenorrhea
[145]. The analgesic efficacy of diclofenac potassium im-
mediate-release tablets in the treatment of ankle sprains
was superior to that of placebo, ibuprofen, and piroxicam
[141–143]. Generally, AEs were infrequent, and no serious
AEs were reported in these studies. The most common AEs
were GI disorders, with diarrhea reported most often by the
patients in active treatment groups [141–143]. Diclofenac
potassium immediate-release tablets were approved by the
FDA in 1993 and are indicated for the relief of acute and
chronic signs and symptoms of osteoarthritis and rheuma-
toid arthritis and the relief of mild-to-moderate pain and
treatment of primary dysmenorrhea [29]. In comparison
with diclofenac sodium enteric-coated tablets, a single oral
dose of diclofenac potassium immediate-release provided
significantly faster analgesia in patients with moderate-to-
severe postoperative pain [21].
Diclofenac potassium immediate-release tablets were
also evaluated in patients with acute migraine headaches.
The rapid and effective analgesia reported for diclofenac in
studies in other acute pain conditions and the potent anti-
inflammatory activity of diclofenac were considered to be
potentially beneficial in preventing neurogenic inflamma-
tion, one of the major causes underlying migraine attacks
[146, 147]. In clinical studies, diclofenac potassium im-
mediate-release tablets were reported to be effective in
relieving migraine pain and provided significant pain relief
1–2 h following initial dosing [147, 148]. In one study,
diclofenac potassium immediate-release tablets appeared to
be as efficacious as, but better tolerated than, the serotonin
agonist sumatriptan, a first-line agent commonly prescribed
for the relief of migraine headache [147]. Diclofenac-
potassium immediate-release doses 50 and 100 mg were
well tolerated, with reduced incidence of nausea compared
with placebo or sumatriptan 100 mg. Furthermore, a larger
proportion of patients evaluated the overall tolerability of
diclofenac-potassium immediate-release tablets as better
than that of sumatriptan [147]. These data suggest that
diclofenac potassium was likely to find a role in the
treatment of migraine headaches.
6.2 Diclofenac Potassium Powder for Oral Solution
for Treatment of Migraine Headaches
Early studies of diclofenac sodium demonstrated rapid
absorption when administered in liquid solution [71, 79].
The diclofenac potassium powder for oral solution
(CAMBIATM, Depomed, Inc., Newark, CA, USA) consists
of diclofenac potassium salt, sweeteners, and flavoring
agents, and a dynamic bicarbonate buffering agent that
could prevent diclofenac potassium from precipitating in
the stomach under acidic conditions [35]. When dissolved
in water and ingested, diclofenac potassium powder for
oral solution results in rapid diclofenac absorption into the
systemic circulation [76]. In the initial PK study in healthy
volunteers, peak plasma concentrations were attained
within 10–15 min after dosing (Table 2) [76]. Furthermore,
the prompt absorption of diclofenac potassium was ac-
companied by the presence of only a single plasma di-
clofenac peak [76].
In patients with migraine headaches, diclofenac potas-
sium powder for oral solution demonstrated improved
analgesia, with the onset of pain relief as early as 15 min
following administration, compared with 60 min following
administration of diclofenac potassium immediate-release
tablets. These results suggest that administration of the
drug as an oral solution may have contributed to more rapid
onset of absorption and pain relief [149, 150]. Significant
reduction in headache intensity and sustained relief were
also demonstrated when compared with diclofenac imme-
diate-release tablets and placebo [150]. Adverse events
related to treatment with diclofenac potassium powder for
oral solution that were reported in[1 % of study par-
ticipants included nausea, dyspepsia, vomiting, and
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dizziness [150]. Diclofenac potassium powder for oral so-
lution is the only FDA-approved NSAID indicated for the
acute treatment of migraine attacks with or without aura in
adults [35] (Table 1).
6.3 Diclofenac Potassium Liquid-Filled Soft Gelatin
Capsules
Diclofenac potassium liquid-filled capsules (ZIPSOR,
Depomed, Inc.) were developed using the patented
ProSorb dispersion technology that combines a mixture
of liquid formulation of diclofenac potassium with
solubilizing and dispersing agents to maximize the ab-
sorption of diclofenac from the stomach and to reduce
variability in the absorption pattern. The main concept of
this technology relies upon the fact that weakly acidic
drugs admixed with solubilizing and dispersing agents will
be absorbed from the stomach at accelerated rates [151].
The inactive ingredients in this formulation are pre-
dominantly non-aqueous and include polyethylene glycol
400, glycerin, sorbitol, povidone, polysorbate 80, hy-
drochloric acid, isopropyl alcohol, and mineral oil [152].
As a result, the product can be manufactured and admin-
istered as an oral dosage form comprising the liquid fill in
soft gelatin capsules [36]. The capsule shells contain ge-
latin, sorbitol, isopropyl alcohol, glycerin, and mineral oil
[36].
In phase I studies in healthy volunteers, diclofenac
potassium liquid-filled soft gelatin capsules demonstrated
rapid and predictable absorption with shorter time to Cmax
compared with diclofenac potassium immediate-release
tablets [115] (Table 2). A 50-mg dose achieved sig-
nificantly shorter tmax and higher Cmax than the 50-mg di-
clofenac potassium tablet, and the Cmax following the
25-mg dose was equivalent to that following administration
of the 50-mg diclofenac potassium tablet. Plasma diclofe-
nac concentration–time courses for the diclofenac potassi-
um 50-mg tablet produced multiple peaks compared with
one peak obtained for diclofenac potassium liquid-filled
soft gelatin capsules (Table 2) [112].
Diclofenac potassium liquid-filled capsules 25 mg, ad-
ministered every 6 h, provided significantly faster onset of
analgesia than placebo in patients with acute pain follow-
ing third molar extraction [153, 154] or bunionectomy
surgery [155, 156]. Diclofenac potassium liquid gel-filled
capsules were generally well tolerated. In the study of
patients following bunionectomy, fewer patients in the
active treatment group (20.6 %) than in the placebo group
(44.4 %) reported AEs. The most commonly reported AEs
in this study included nausea, headache, vomiting, and
constipation [155]. The generally high proportion of pa-
tients reporting AEs in the placebo group was attributed to
the significantly increased number of patients requiring
opioid-containing rescue medication. Diclofenac potassium
liquid-filled soft gelatin capsules were approved by the
FDA in 2009 for the relief of mild-to-moderate acute pain
in adults [36].
7 Topical Formulations of Diclofenac Sodium
or Epolamine Salt for Local Treatment
Topical diclofenac sodium preparations were developed
with the aim of treating local pain and inflammation while
limiting diclofenac systemic exposure and potentially
minimizing the risk of AEs associated with treatment with
systemic NSAIDs. As an organic acid, diclofenac is lipo-
philic, while its salts are water soluble at neutral pH. The
combination of these two properties renders diclofenac
capable of penetrating through cell membranes, including
the synovial lining of diarthrodial joints and the skin [47].
Studies performed in 1997 and 2001 reported that di-
clofenac had excellent transdermal penetration properties
[157, 158]. Based on the favorable permeation properties
along with strong inhibition of PGE2 synthesis, diclofenac
was expected to exert potent anti-inflammatory activity
when applied topically [47, 158]. Several diclofenac for-
mulations have been developed for transdermal delivery,
including diclofenac sodium gels, diclofenac sodium topi-
cal solutions, and a diclofenac epolamine patch [93].
Although topical NSAIDs are widely used outside the
USA [159, 160], diclofenac sodium is the only NSAID
approved by the FDA for topical use in the treatment of
pain associated with osteoarthritis. The dispensed pre-
scriptions for topical diclofenac products constituted ap-
proximately 3 % of the total annual prescriptions for
NSAIDs in the USA in 2012 [19]. Topical diclofenac drug
products include diclofenac sodium topical gel 1 %
(Voltaren Gel, Novartis Consumer Health, Inc., Parsip-
pany, NJ, USA) [34], approved by the FDA in 2007 and
indicated for the relief of pain of osteoarthritis of joints
amenable to topical treatment such as the knees and hands,
and diclofenac sodium topical solution 1.5 and 2 %
(PENNSAID Mallinckrodt Brand Pharmaceuticals, Inc.,
Hazelwood, MO, USA), indicated for the treatment of
signs and symptoms of osteoarthritis of the knee [37], ap-
proved in 2009 (1.5 %) and 2014 (2 %) (Table 1). The
American College of Rheumatology and the American
Academy of Orthopedic Surgeons guidelines have recently
recommended use of topical NSAIDs for treatment of os-
teoarthritis of the hand or knee, especially in patients older
than 75 years or those with increased GI risk [161–164].
NSAIDs administered topically usually achieve only
3–5 % of total systemic absorption for oral diclofenac
products. On the other hand, interstitial concentrations of
diclofenac in the muscle tissue are usually higher after
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topical treatment than after oral administration of NSAIDs
[165]. PK studies in healthy volunteers who received
topical diclofenac and other topical NSAID preparations
available in Europe demonstrated that peak plasma levels
constituted less than 10 % of the Cmax achieved following
oral administration [166]. The maximal plasma concen-
trations were achieved approximately ten times later fol-
lowing topical diclofenac administration compared with
administration of an equivalent oral dose of diclofenac.
The analgesic and anti-inflammatory efficacy of di-
clofenac sodium topical preparations have been
documented in several clinical studies. The efficacy of 1 %
diclofenac sodium topical gel in patients with osteoarthritis
of the knee treated for 3–12 weeks was superior to placebo
in reducing pain intensity and average pain on movement
and in improving physical function [167, 168]. In patients
with knee osteoarthritis, treatment with diclofenac sodium
1.5 % topical solution combined with dimethyl sulfoxide
led to significant reduction in pain and improvement in
physical function, as well as relief of joint stiffness, com-
pared with placebo or dimethyl sulfoxide vehicle [169,
170]. In two studies, efficacy of diclofenac sodium 1.5 %
topical solution was comparable to that of oral diclofenac
[171].
Because patients with osteoarthritis of the knee are
likely to use topical NSAIDs over the course of many
years, it is important to gain an understanding of their long-
term safety. Diclofenac gel or topical solution administra-
tion in long-term studies (up to 52 weeks’ duration) were
generally well tolerated, and the most frequent reported
AEs were dry skin at the application site (25.3 % of pa-
tients), contact dermatitis (13.0 %), and contact dermatitis
with vesicles (9.5 %) [172]. Due to lower circulating di-
clofenac levels, patients administered diclofenac sodium
topical solution experienced fewer GI-associated AEs than
did patients treated with oral diclofenac (6.5 vs. 23.8 %)
[173]. Serious GI AEs associated with topical diclofenac
treatments are rare [166, 174].
Compared with diclofenac sodium and potassium salts,
the epolamine salt of diclofenac demonstrates detergent-
like properties with improved solubility in both water and
organic solvents, facilitating enhanced epidermal penetra-
tion [47, 175]. Clinical studies in patients experiencing
acute pain from minor soft tissue injuries or ankle sprains
reported that diclofenac epolamine topical patches pro-
vided rapid and effective local analgesia compared with
placebo and were generally safe and well tolerated [176–
178]. Diclofenac epolamine (FLECTOR IBSA Institut
Biochimique SA, Lugano, Switzerland) 1.3 % patches
(10 9 14 cm) containing 180 mg of diclofenac were ap-
proved by the FDA in 2007. They are indicated for topical
treatment of acute pain due to minor strains, sprains, and
contusions, with the recommended twice-daily changes of
the patch [33]. In patients with acute musculoskeletal
conditions or osteoarthritis, treatment for 2–3 weeks with
diclofenac epolamine patches did not lead to any serious
AEs in the GI tract, kidneys, or liver. The majority of AEs
included skin reactions, most commonly pruritus in both
placebo-treated and diclofenac epolamine patch-treated
patients. A comparison with diclofenac gel suggested that
pruritus was most likely secondary to the presence of the
plaster component of the patch [47].
Altogether, these data suggest that topical NSAID
preparations are suitable for treatment of a subset of pa-
tients with acute pain following injury or osteoarthritis
amenable to local application of gel or solution, but not for
management of inflammation of multiple joints that may be
difficult to access or for systemic treatment of
inflammation.
8 Injectable Diclofenac
Injectable diclofenac drug products have been available in
the UK since 1997 and are available globally [179, 180].
These drug products often consist of ampules containing
diclofenac 75 mg and used propylene glycol and benzyl
alcohol as solubilizing agents and have required a lengthy
infusion time when administered intravenously [181]. An
injectable diclofenac drug product has been developed and
approved in the USA for use in patients with moderate pain
or as part of a multimodal analgesic regimen for control of
perioperative pain [40, 181]. This diclofenac formulation
(DylojectTM, Hospira Inc., Lake Forest, IL, USA) contains
diclofenac sodium 37.5 mg and includes hydroxypropyl-b-
cyclodextrin (HPbCD) to enhance solubility (333 mg per
mL of water), along with pH modifiers and monothio-
glycerol [40, 181]. Unlike other diclofenac sodium for-
injection drug products, HPbCD-diclofenac is propylene
glycol-free, and the improved solubility allowed conve-
nient preparation of HPbCD-diclofenac and a shorter in-
fusion period [181]. HPbCD-diclofenac administration
intravenously or via intramuscular injection provided
equivalent bioavailability compared with intravenous or
intramuscular administration of an injectable diclofenac
sodium drug product containing propylene glycol
(Voltarol, Novartis Pharmaceuticals UK Ltd, Camberly,
UK) in healthy volunteers [181]. HPbCD-diclofenac 75 mg
provided rapid pain relief in patients with postoperative
pain following impacted molar extraction compared with
placebo [182] and also provided significantly greater re-
ductions in pain intensity and improved tolerability com-
pared with a 75-mg dose of injectable diclofenac sodium
drug product containing propylene glycol (Voltarol) in a
similar study of patients with postoperative dental pain
[183]. HPbCD-diclofenac administered intravenously
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produced significantly greater reductions in pain intensity
and lower rates of opioid-rescue medication use compared
with placebo in patients experiencing pain following
orthopedic surgery [184]. These results suggest that di-
clofenac sodium injection for intravenous use is a suitable
option for patients experiencing acute postoperative pain or
as part of a multimodal analgesic strategy to achieve pe-
rioperative pain control.
9 SoluMatrix Diclofenac Acid
SoluMatrix diclofenac (ZORVOLEX, Iroko Pharmaceu-
ticals LLC, Philadelphia, PA, USA) was approved in the
USA in 2013. Unlike other diclofenac drug products that
contain sodium, potassium, or epolamine salts of diclofe-
nac, the active ingredient in SoluMatrix diclofenac is the
diclofenac molecule in its neutral, un-ionized (free car-
boxylic acid) form (Fig. 1) [39]. Thus, SoluMatrix di-
clofenac capsules are not interchangeable with other
diclofenac products containing diclofenac potassium or
sodium salts.
Salt forms of the drug, which are soluble in water at
neutral pH, will precipitate in acidic conditions such as
those that are found in the stomach. Without modification
of the starting material, subsequent dissolution of the active
ingredient may be variable or slow due to the presence of
large or agglomerated particles [185, 186]. SoluMatrix
Fine Particle TechnologyTM is a proprietary process that
produces drug particles that are 200–800 nm in diameter
without altering the chemical properties of the active
therapeutic ingredient [116]. The dry milling process in-
creases drug particle surface area relative to mass, resulting
in improved dissolution properties compared with di-
clofenac potassium immediate-release tablets, promoting
rapid absorption [187].
SoluMatrix diclofenac capsules were developed to pro-
duce efficacy at reduced doses, aligned with recommen-
dations by health authorities including the FDA and the
European Medicines Agency that NSAIDs should be pre-
scribed at the lowest effective dose for the shortest possible
duration [188]. SoluMatrix diclofenac 18 and 35-mg doses
contain 20 % less active ingredient on a molar basis than
25 and 50-mg diclofenac potassium immediate-release
tablets, respectively. Under fasting conditions, a single
dose of SoluMatrix diclofenac 35 mg achieved a 23 %
lower overall systemic exposure (area under the concen-
tration–time curve from time 0 extrapolated to infinity
[AUC0–?]) and lower Cmax but similar tmax compared with
the diclofenac potassium immediate-release tablets 50 mg
(Table 2) [116, 189].
The analgesic efficacy of low-dose SoluMatrix diclofe-
nac has been investigated in two phase III studies. In
patients experiencing pain following bunionectomy,
SoluMatrix diclofenac 18 or 35 mg administered three
times daily provided rapid and significantly greater pain
relief over 48 h than did placebo [189]. In patients with
osteoarthritis of the hip or knee, treatment with SoluMatrix
diclofenac 35 mg administered three times daily over
12 weeks significantly reduced pain measures (at rest or
associated with usual activities) and improved composite
indices of pain, function, and stiffness compared with
placebo [182]. Based on the cumulative daily dose of
18 mg three times daily, SoluMatrix diclofenac represents
the lowest-dose diclofenac option for the systemic treat-
ment of acute pain.
In both controlled phase III studies, all doses of
SoluMatrix diclofenac capsules were generally well toler-
ated, and AEs were generally of mild-to-moderate intensity
[189, 190]. In the bunionectomy study, the most frequent
non-procedure–related AEs ([5 %) included nausea,
headache, dizziness, vomiting, and constipation [189]. In
the 12-week osteoarthritis study, the most frequent AEs
([5 %) for diclofenac 35 mg three times daily included
nausea, diarrhea, and headache [190]. Few serious GI, CV,
or renal AEs were reported in these studies [189, 190].
SoluMatrix diclofenac is indicated for the management of
acute and osteoarthritis pain [39].
10 Conclusions
Continuous improvements in biopharmaceutical properties
of diclofenac have led to the creation of a broad array of
drug products designed to treat multiple inflammatory and
painful conditions. The development of diclofenac drug
products began with a molecule with physicochemical and
steric properties considered to represent the ideal NSAID.
The first diclofenac drug product, diclofenac sodium en-
teric-coated tablets, was developed with the aim of re-
ducing the risk of GI AEs commonly associated with the
use of NSAIDS. Subsequent efforts focused on improving
dosing convenience through development of an extended-
release diclofenac sodium preparation. The development of
a fixed-dose combination of diclofenac sodium and a gas-
troprotective agent, misoprostol, a synthetic prostaglandin,
or co-administration of a diclofenac enteric-coated tablet
with proton pump inhibitors provided an alternative ap-
proach to enhance GI tolerability. The enhanced dissolu-
tion and absorption kinetics of diclofenac potassium led to
the development of several diclofenac potassium-contain-
ing drug products, with the ultimate goal of shortening the
time to clinically meaningful analgesia. These include di-
clofenac potassium immediate-release tablets, diclofenac
potassium powder for oral solution, and diclofenac potas-
sium liquid-filled soft gelatin capsules. The development of
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topical diclofenac preparations permitted local treatment of
pain and inflammation in the subset of patients with readily
accessible sites of osteoarthritis, and improved the safety
profile of diclofenac by minimizing its systemic exposure.
SoluMatrix diclofenac is a new drug product consisting of
submicron drug particles with enhanced dissolution prop-
erties designed to provide efficacy at reduced doses and
constitutes the lowest dose treatment option for the sys-
temic treatment of acute pain. Diclofenac is as an excellent
example of how pharmaceutical technology can create new
drug products that continue to be useful in clinical practice,
using existing molecules.
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